70 likes | 237 Views
Oncologia:novità su onco-metabolismi e connesse terapie integrate fito bio - enzinutri -dinamiche . PROBIOTICI:usi innovativi multiattivi e connesse terapie in oncologia, gastroenteroL ., metab ., antietà,ecc . NATURFIERA-CATANIA- 8GIU.2013 Prof . Calogero Rinzivillo
E N D
Oncologia:novità su onco-metabolismi e connesseterapie integrate fitobio-enzinutri-dinamiche.PROBIOTICI:usi innovativi multiattivie connesse terapiein oncologia,gastroenteroL.,metab.,antietà,ecc. NATURFIERA-CATANIA-8GIU.2013 Prof. Calogero Rinzivillo Farmacista-medico specialista 3394201756-3293178092-0953782378 095435565-rinzivil@unict.itt nucli@policlinico.unict.it VICEPRES.AMIFIT-ASS.IT.MED.INTEGR.FITOT. - Az. Osped.Universit.Policlinico Vittorio Emanuele-Edif.4-via S. Sofia- Catania
Presidente Dr.a Patrizia Tosto 14 Apr.2013-Paradiso Etna-1°CongressoNaz. A.M.I.Fit.Ass.Italiana Medicina Integrata e Fitoterapia-
Prof. C. Rinzivillo (Passione,studio NutriFitoInt.e ter.nat.integr.daì76 =oltre 35anni) (Cent. m.: Erythraea centaurium, fosfat. col.) Lauree:Farmacia, Medic.e Special.max voti,lode e proposta premi Premio Fondazione Internazionale “G.GALILEI” (Ginevra) e Premio Lions per ricerca medica e nutrizione; Relazione premiata Congresso Nazionale ADI-Giardini-Ass.Diet.Nutr.Clin.(uso integratori alimentari e cofattori e proteine in operati oncologici stomizzati, preventive o per deficit nutrizionali) Oltre 150 pubblicazioni scientifiche su temi di gastroenterologia, nutrizione clinica, supporto in chirurgia, gastroent.,oncologia, malattie metaboliche,medicina benessere e antinvecch.,fito-nutri-int. Finanz.vari progetti Ateneo\Dip.:terapie mediche integrate,in partic.paz.Chir.,Oncol.,App.dig.,Metab già o attuale Socio varie Soc.Medico-Scientifiche, fra cui:° New York Academy of Sciences, ° ADI-Ass. Ital.Diet.Nutriz.Clinica, ° SINPE Soc.Ital. Nutrizione Parent. Enterale, ° AIOT- Ass.It.OmeoTossic.-Medic.Biologica- MEDIBIO; °MASTER Annuale e socio AMIDEAV Ass.Medica Ital.Elettr.Agopunt.; ecc. Resp.1°Prog.Ricerca Finaliz.Sanit.Reg.”NUTRI-FITOINTEGRAT. IN PAZ. CHIRURG.,ONCOL.,DISMETAB.”
ONCOLOGIA • principio attivo antiinfiammat.dellacurcuma,tradizionale per secoli AY,MTCinese. • capacità curcumina causare apoptosi solo negli ONCOCITI mentre miglioravan funzioni ‘normali’ di cellule normali-ANDERSON CANCER CENTER TEXAS 2011 • Ciò è confermato da Ospedale Zheijian-Cina, in particolare apoptosi in cellule del BC cancro mammario TNBC=triplo negativo (recettori E,P, EGrF), più difficile da curare dei BC recett.+. • Tale effetto è potenziato se si usano cibi e integratori ricchi di flavanoli, in particolare epigallocatechina gallato (EGCG) del tè verde, effetti ottimi antiox e anti-neoangiogenetico antiflog.se usato con diferuloilmetano da curcumina. • SITI WWW. : -greenmedinfo.com/substance/curcumin; • naturalnews.com/037879_curcumin_cancer_cells_turmeric.html • ncbi.nlm.nih.gov/pubmed/23740392 (Singh&Misra.Interdisc.Sc.2013 June) (diferuloylmethane) and itsnaturallyanalogsdemethoxy, bisdemethoxy and cyclocurcumin, present in rhizomes of curcuma speciesturmeric, inhibit the proliferation of a wide variety of tumorcells. AA.shows thatCurcumin targets (EpiG.n)nuclearprotein HPV16E6,major proteinactivelydevelopingoral&cervical K • Curr Cancer Drug Targets,2013 Apr 17. [ahead of print], ClinicalOncology, Queen Elizabeth Hospital- HONG KONG-By Wang Y e C.: Genetic And Epigenetic Studies For Determining Molecular Targets Of Natural Product Anticancer Agents->EGCG, curcumin, genistein, sulforaphane and resveratrolhaveanticancerpropertiesthrough the mechanisms of alteringepigeneticprocesses[including DNA methylation, histonemodification, chromatinremodeling, microRNA (miRNA) regulation] and targetingcancerstemcells(CSCs)
ONCOLOGIA • Chem.Commun.(Cambridge Press) 2013 Jul-Cl.studyc3cc41858h. Ahead of PRINT Chemicalproteomics-drivendiscovery of oleocanthalas an Hsp90 inhibitor. by Margarucci L. e C.-Dipart.FarmaciaUniv. Salerno- Hsp90 is a key target in cancer therapy. Oleocanthal, olive oil active compound, is its inhibitor. • NutrMetabCardiovasc Dis.2013 Feb 25.(ahead of print] Mediterraneandiet and non enzymaticantioxidantcapacity in the PREDIMED study: Evidence for a mechanism of antioxidanttuning. By Zamora R.e C. 1-year of correct MED diet increases plasma TAC:TOTAL ANTIOXIDANT Capacity level. • Colloids Surf B Biointerfaces.2013 Jun.Ahead of print.ElsevierScient.Intern.Publish.Spontaneous ultra fast synthesis of goldnanoparticlesusingPunica granatumfor cancertargeteddrugdelivery.-ByGaneshkumarM.&C.-India-CSIRCounc.Scient.Ind.Res. Free 5-Fu,vs 5Fu@Pun.NanoPs was investigated against MCF-7 cells (breast cancer)and we observed that amount of 5Fluoruracil(CH)required to achieve 50%of growth-inhibition was much lower VS free 5Fu. • ->cytochrome P450 enzyme, CYP1B1, is a target in prostate cancer.Compoundsinhibiting CYP1B1 activity are contemplated to exertbeneficialeffectsatthreestages of prostate cancerdevelopment, thatis, initiation, progression, and development of drugresistance. Pomegr.ellagitannins/intest.microbialmetabolites/: Urolithin A was the most potent uncompetitive inhibitor of CYP1B1,with a dual mode mechanism by decreasing CYP1B1 metabolic activity and expression (epigenetics).Punicalins and punicalagins exhibited potent CYP1A1 inhibition, also-J Agric Food Chem.2009 Nov<-Missisippi Un.->AND J Agric Food Chem.2010 Feb: Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins
ONCOLOGIA • J Mol Endocrinol.2013 May 29. [Ahead of print] Antioxidant and anti-growth action of peracetylatedoleuropein in thyroid cancer BulottaS.e C. phenolic components oleuropein and its derivatives.OLE inhibited significantly proliferation This effect was paralleled by a reduction of basal phospho-Akt and phospho-ERK levels and H2O2induced ROS levels. A stronger effect by Ac-OLE in inhibiting cell growth and as antioxidant(vitro). • Cytotechnology.-2009 Jan;59(1) Anti-proliferative and apoptotic effects of oleuropein and hydroxytyrosol on human breast cancer-University of Tsukuba-Japan-by Han J. & c.- • Effects of anthocyanidins (cyanidin, delphinidin, malvidin, peonidin, petunidin, pelargonidin) on the arylhydrocarbonreceptor (AhR)-CYP1A1 signalingpathway in human hepatic&intest.Kcells. Pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity -UNIV. BARCELLONA (Zamora R. e C.) staapprofondendo DIETA MED.eeffettisuoiprincipiattivigiàdimostrati in vivo e vitro come antiox e antitum.disupporto PRINCIPI (MALVIDINA ecc.): vedi Br. J. Nutrition 2012 e altreriviste s
ONCOLOGIA • PASTEUR EFFECT • WARBURG EFFECT • REVERSE WARBURG EFFECT (LISANTI) • CRABTREE EFFECT NUTRIENTI ENZIMATIZZATI BIODINAMICI OTTIMIZZATI